

# Michael McClung

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6141056/michael-mcclung-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210  
papers

19,061  
citations

70  
h-index

136  
g-index

235  
ext. papers

21,781  
ext. citations

6.6  
avg, IF

6.61  
L-index

#	Paper	IF	Citations
210	Denosumab for prevention of fractures in postmenopausal women with osteoporosis. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 756-65	59.2	2189
209	Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 333-40	59.2	1530
208	Denosumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 821-31	59.2	931
207	Romosozumab in postmenopausal women with low bone mineral density. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 412-20	59.2	781
206	Osteoporosis. <i>Lancet, The</i> , <b>2019</b> , 393, 364-376	40	578
205	Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. <i>Endocrine Reviews</i> , <b>2005</b> , 26, 688-703	27.2	538
204	Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. <i>New England Journal of Medicine</i> , <b>1998</b> , 338, 485-92	59.2	428
203	Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. <i>Bone</i> , <b>2008</b> , 43, 222-229	4.7	408
202	Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. <i>Archives of Internal Medicine</i> , <b>2005</b> , 165, 1762-8		337
201	Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. <i>American Journal of Medicine</i> , <b>2013</b> , 126, 13-20	2.4	326
200	Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 190-198	6.3	306
199	Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. <i>American Journal of Medicine</i> , <b>1995</b> , 99, 144-52	2.4	296
198	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. <i>Endocrine Practice</i> , <b>2003</b> , 9, 544-64	3.2	290
197	The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. <i>Calcified Tissue International</i> , <b>2002</b> , 71, 103-11	3.9	274
196	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. <i>Endocrine Practice</i> , <b>2010</b> , 16 Suppl 3, 1-37	3.2	263
195	Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 141-51	6.3	251
194	Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. <i>Journal of Bone and Mineral Research</i> , <b>2007</b> , 22, 1832-41	6.3	239

193	Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 1315-22	6.3	230
192	Effects of denosumab on fracture and bone mineral density by level of kidney function. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 1829-35	6.3	225
191	Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. <i>Journal of Bone and Mineral Research</i> , <b>2010</b> , 25, 937-47	6.3	213
190	Official positions of the international society for clinical densitometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 3651-5	5.6	211
189	Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 242-51	6.3	196
188	The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. <i>Annals of Internal Medicine</i> , <b>1990</b> , 112, 29-34	8	181
187	Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. <i>Annals of Internal Medicine</i> , <b>1998</b> , 128, 253-61	8	180
186	Fracture risk remains reduced one year after discontinuation of risedronate. <i>Osteoporosis International</i> , <b>2008</b> , 19, 365-72	5.3	178
185	Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. <i>Clinical Therapeutics</i> , <b>1999</b> , 21, 1025-44	3.5	168
184	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. <i>Endocrine Practice</i> , <b>2020</b> , 26, 1-46	3.2	164
183	Discrepancies in normative data between Lunar and Hologic DXA systems. <i>Osteoporosis International</i> , <b>1996</b> , 6, 432-6	5.3	159
182	Quantitative ultrasound of the heel: correlation with densitometric measurements at different skeletal sites. <i>Osteoporosis International</i> , <b>1994</b> , 4, 42-7	5.3	156
181	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 530-7	6.3	155
180	Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. <i>Journal of the American Geriatrics Society</i> , <b>2004</b> , 52, 1832-9	5.6	145
179	Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1997</b> , 82, 265-74	5.6	143
178	Vertebral Fractures: Clinical Importance and Management. <i>American Journal of Medicine</i> , <b>2016</b> , 129, 2211-10	5.1	139
177	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 687-93	6.3	139
176	A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 3161-9	5.6	138

175	Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. <i>Bone</i> , <b>2007</b> , 41, 122-8	4.7	136
174	Observations following discontinuation of long-term denosumab therapy. <i>Osteoporosis International</i> , <b>2017</b> , 28, 1723-1732	5.3	125
173	Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 935-42	8	125
172	Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 15-28	3.5	124
171	Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. <i>American Journal of Medicine</i> , <b>1997</b> , 103, 291-7	2.4	119
170	Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2006</b> , 91, 2631-7	5.6	118
169	Enhanced precision with dual-energy X-ray absorptiometry. <i>Calcified Tissue International</i> , <b>1992</b> , 51, 14-7	3.9	117
168	Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. <i>Contraception</i> , <b>2008</b> , 77, 67-76	2.5	112
167	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 1119-33	6.3	111
166	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 394-402	5.6	111
165	Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. <i>Osteoporosis International</i> , <b>2015</b> , 26, 699-712	5.3	105
164	Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. <i>Journal of Bone and Mineral Research</i> , <b>1998</b> , 13, 1032-8	6.3	105
163	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 211-8	6.3	103
162	Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study. <i>Journal of Bone and Mineral Research</i> , <b>2018</b> , 33, 1397-1406	6.3	99
161	Quality control of DXA instruments in multicenter trials. <i>Osteoporosis International</i> , <b>1995</b> , 5, 218-27	5.3	96
160	Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. <i>Journal of Clinical Densitometry</i> , <b>2006</b> , 9, 22-30	3.5	93
159	Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. <i>Osteoporosis International</i> , <b>2013</b> , 24, 227-35	5.3	92
158	Automated evaluation of hip axis length for predicting hip fracture. <i>Journal of Bone and Mineral Research</i> , <b>1994</b> , 9, 1065-70	6.3	92

157	Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2001</b> , 86, 4717-26	5.6	92
156	Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. <i>Journal of Bone and Mineral Research</i> , <b>2011</b> , 26, 397-404	6.3	88
155	Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. <i>Menopause</i> , <b>2006</b> , 13, 377-86	2.5	87
154	Alendronate improves bone mineral density in elderly women with osteoporosis residing in long-term care facilities. A randomized, double-blind, placebo-controlled trial. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 742-6	8	87
153	Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. <i>Obstetrics and Gynecology</i> , <b>2009</b> , 114, 999-1007	4.9	86
152	Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab. <i>Journal of Bone and Mineral Research</i> , <b>2014</b> , 29, 158-65	6.3	85
151	Femoral strength in osteoporotic women treated with teriparatide or alendronate. <i>Bone</i> , <b>2012</b> , 50, 165-70	4.7	85
150	Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: recovery following discontinuation. <i>Contraception</i> , <b>2006</b> , 74, 90-9	2.5	85
149	Changes in bone density and turnover after alendronate or estrogen withdrawal. <i>Menopause</i> , <b>2004</b> , 11, 622-30	2.5	83
148	Fine-needle aspiration cytology in the preoperative diagnosis of thyroid nodules. <i>Annals of Internal Medicine</i> , <b>1977</b> , 87, 265-9	8	83
147	Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. <i>Bone</i> , <b>2008</b> , 42, 36-42	4.7	81
146	A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1335-42	5.6	80
145	Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 3482-6	5.6	79
144	The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. <i>Journal of the American Dental Association</i> , <b>2010</b> , 141, 1365-70	1.9	76
143	Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2004</b> , 19, 11-8	6.3	76
142	Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. <i>Osteoporosis International</i> , <b>2011</b> , 22, 1725-35	5.3	71
141	Effects of atorvastatin on bone in postmenopausal women with dyslipidemia: a double-blind, placebo-controlled, dose-ranging trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 4671-7	5.6	70
140	Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry. <i>Seminars in Arthritis and Rheumatism</i> , <b>1996</b> , 25, 361-72	5.3	70

139	Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2000</b> , 85, 1492-7	5.6	67
138	Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2004</b> , 89, 4879-85	5.6	66
137	A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. <i>American Journal of Clinical Nutrition</i> , <b>1996</b> , 64, 354-60	7	62
136	Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. <i>Lancet Diabetes and Endocrinology</i> , <b>2019</b> , 7, 899-911	18.1	61
135	Development and validation of the mini-osteoporosis quality of life questionnaire (OQLQ) in osteoporotic women with back pain due to vertebral fractures. Osteoporosis Quality of Life Study Group. <i>Osteoporosis International</i> , <b>1999</b> , 10, 207-13	5.3	60
134	Denosumab rapidly increases cortical bone in key locations of the femur: a 3D bone mapping study in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 46-54	6.3	59
133	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS- 2020 UPDATE. <i>Endocrine Practice</i> , <b>2020</b> , 26, 564-570	3.2	59
132	Bisphosphonates. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2003</b> , 32, 253-71	5.5	54
131	Yearly zoledronic acid in postmenopausal osteoporosis. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 712-3; author reply 714-5	59.2	54
130	Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1827-1834	6.3	52
129	Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab. <i>Bone</i> , <b>2013</b> , 56, 482-8	4.7	51
128	Role of RANKL inhibition in osteoporosis. <i>Arthritis Research and Therapy</i> , <b>2007</b> , 9 Suppl 1, S3	5.7	51
127	The Long-Term Effect Of Specific Type II 5 $\alpha$ -Reductase Inhibition With Finasteride on Bone Mineral Density in Men: Results of a 4-Year Placebo Controlled Trial. <i>Journal of Urology</i> , <b>2002</b> , 167, 2105-2108	2.5	51
126	Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2017</b> , 9, 263-270	3.8	49
125	Effects of risedronate on fracture risk in postmenopausal women with osteopenia. <i>Osteoporosis International</i> , <b>2008</b> , 19, 681-6	5.3	49
124	Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. <i>Osteoporosis International</i> , <b>2008</b> , 19, 1039-45	5.3	48
123	American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations. <i>Endocrine Practice</i> , <b>2010</b> , 16, 1016-9	3.2	43
122	Creation of an age-adjusted, dual-energy x-ray absorptiometry-derived trabecular bone score curve for the lumbar spine in non-Hispanic US White women. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 314-9	3.5	42

121	Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, 4691-701	5.6	40
120	The relationship between bone mineral density and fracture risk. <i>Current Osteoporosis Reports</i> , <b>2005</b> , 3, 57-63	5.4	40
119	Romozosumab for the treatment of osteoporosis. <i>Osteoporosis and Sarcopenia</i> , <b>2018</b> , 4, 11-15	2.3	39
118	Bisphosphonates in osteoporosis: recent clinical experience. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 225-38	4	39
117	Tiludronate therapy for Paget's disease of bone. <i>Bone</i> , <b>1995</b> , 17, 493S-496S	4.7	39
116	Denosumab significantly increases DXA BMD at both trabecular and cortical sites: results from the FREEDOM study. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 147-53	3.5	38
115	Comparison of proximal femur and vertebral body strength improvements in the FREEDOM trial using an alternative finite element methodology. <i>Bone</i> , <b>2015</b> , 81, 122-130	4.7	37
114	Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. <i>Osteoporosis International</i> , <b>2012</b> , 23, 267-76	5.3	36
113	The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. <i>Bone</i> , <b>2003</b> , 32, 421-6	4.7	33
112	Bone Mineral Density After Transitioning From Denosumab to Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	33
111	Serum protein concentrations and bone mineral content in aging normal men. <i>American Journal of Clinical Nutrition</i> , <b>1987</b> , 46, 614-21	7	32
110	Treatment of postmenopausal osteoporosis with delayed-release risedronate 35mg weekly for 2 years. <i>Osteoporosis International</i> , <b>2013</b> , 24, 301-10	5.3	30
109	Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis: bone density, mass, and strength of the radius, and wrist fracture. <i>Menopause</i> , <b>2013</b> , 20, 130-7	2.5	30
108	Evidence that increased calcium intake does not prevent early postmenopausal bone loss. <i>Clinical Therapeutics</i> , <b>1998</b> , 20, 933-44	3.5	29
107	A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate. <i>Osteoporosis International</i> , <b>2006</b> , 17, 159-66	5.3	29
106	Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. <i>Regulatory Toxicology and Pharmacology</i> , <b>2002</b> , 35, 320-6	3.4	27
105	Blood pressure and calcium intake are related to bone density in adult males. <i>British Journal of Nutrition</i> , <b>1999</b> , 81, 383-388	3.6	27
104	Prediction of fracture risk. I: Bone density. <i>American Journal of the Medical Sciences</i> , <b>1996</b> , 312, 257-9	2.2	27

103	Multisite bone ultrasound measurement on North American female reference population. <i>Journal of Clinical Densitometry</i> , <b>2001</b> , 4, 239-48	3.5	25
102	Denosumab densitometric changes assessed by quantitative computed tomography at the spine and hip in postmenopausal women with osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 250-6	3.5	24
101	Do current management strategies and guidelines adequately address fracture risk?. <i>Bone</i> , <b>2006</b> , 38, S13-7	4.7	24
100	Invasive Oral Procedures and Events in Postmenopausal Women With Osteoporosis Treated With Denosumab for Up to 10 Years. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2443-2452	5.6	23
99	Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. <i>Osteoporosis International</i> , <b>2013</b> , 24, 293-9	5.3	23
98	Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study <b>2005</b> , 20, 141		23
97	Bone Mineral Density and Parathyroid Hormone as Independent Risk Factors for Mortality in Community-Dwelling Older Adults: A Population-Based Prospective Cohort Study in Brazil. The São Paulo Ageing & Health (SPAH) Study. <i>Journal of Bone and Mineral Research</i> , <b>2016</b> , 31, 1146-57	6.3	22
96	Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , <b>2017</b> , 28, 2967-2973	5.3	22
95	Therapy for fracture prevention. <i>JAMA - Journal of the American Medical Association</i> , <b>1999</b> , 282, 687-9	27.4	22
94	Emerging Therapies for Osteoporosis. <i>Endocrinology and Metabolism</i> , <b>2015</b> , 30, 429-35	3.5	21
93	Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2013</b> , 5, 199-209	3.8	21
92	Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. <i>Menopause</i> , <b>2018</b> , 25, 767-771	2.5	20
91	Using Osteoporosis Therapies in Combination. <i>Current Osteoporosis Reports</i> , <b>2017</b> , 15, 343-352	5.4	20
90	Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D3 therapy in senile osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>1989</b> , 4, 81-8	6.3	20
89	Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. <i>Bone</i> , <b>2009</b> , 44, 418-22	4.7	20
88	Measurement of body composition in the elderly: dual energy x-ray absorptiometry, underwater weighing, bioelectrical impedance analysis, and anthropometry. <i>Gerontology</i> , <b>1994</b> , 40, 332-9	5.5	20
87	Calcium and cholecalciferol: effects of small supplements in normal men. <i>American Journal of Clinical Nutrition</i> , <b>1988</b> , 48, 127-30	7	20
86	Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. <i>Clinical Interventions in Aging</i> , <b>2009</b> , 4, 445-9	4	19



85	Densitometry of the radius using single and dual energy absorptiometry. <i>Calcified Tissue International</i> , <b>1994</b> , 54, 208-11	3.9	19
84	Peritonitis in children receiving continuous ambulatory peritoneal dialysis. <i>Pediatric Infectious Disease Journal</i> , <b>1983</b> , 2, 328-32	3.4	18
83	Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 992-7	2.4	17
82	The menopause and HRT. Prevention and management of osteoporosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 17, 53-71	6.5	17
81	Familial hypercholesterolaemia and primary hypothyroidism: coexistence of both disorders in a young woman with severe hypercholesterolaemia. <i>Clinical Endocrinology</i> , <b>1981</b> , 14, 145-52	3.4	16
80	Current bone mineral density data on bisphosphonates in postmenopausal osteoporosis. <i>Bone</i> , <b>1996</b> , 19, 195S-198S	4.7	16
79	Bisphosphonates. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , <b>2006</b> , 50, 735-44		15
78	Denosumab for the treatment of osteoporosis. <i>Osteoporosis and Sarcopenia</i> , <b>2017</b> , 3, 8-17	2.3	14
77	Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies. <i>American Journal of Medicine</i> , <b>2017</b> , 130, 862.e1-862.e7	2.4	14
76	Understanding and communicating the benefits and risks of denosumab, raloxifene, and teriparatide for the treatment of osteoporosis. <i>Journal of Clinical Densitometry</i> , <b>2014</b> , 17, 490-5	3.5	14
75	Clinical utility of anti-sclerostin antibodies. <i>Bone</i> , <b>2017</b> , 96, 3-7	4.7	12
74	Osteopenia: to treat or not to treat?. <i>Annals of Internal Medicine</i> , <b>2005</b> , 142, 796-7	8	12
73	Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?. <i>Clinical Obstetrics and Gynecology</i> , <b>2013</b> , 56, 743-8	1.7	11
72	A national random survey of bone mineral density reporting in the United States. <i>Journal of Clinical Densitometry</i> , <b>2002</b> , 5, 3-9	3.5	11
71	Robust norms for neuropsychological tests of verbal episodic memory in Australian women. <i>Neuropsychology</i> , <b>2019</b> , 33, 581-595	3.8	11
70	A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. <i>Osteoporosis International</i> , <b>2020</b> , 31, 2231-2241	5.3	10
69	A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. <i>Journal of Bone and Mineral Research</i> , <b>2020</b> , 35, 1014-1021	6.3	10
68	To FRAX or not to FRAX. <i>Journal of Bone and Mineral Research</i> , <b>2012</b> , 27, 1240-2	6.3	10

67	Acute parathyroid hormone secretory dynamics: hormone secretion from normal primate and adenomatous human tissue in response to changes in extracellular calcium concentration. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1986</b> , 62, 950-5	5.6	10
66	Western Osteoporosis Alliance Clinical Practice Series: Treat-to-Target for Osteoporosis. <i>American Journal of Medicine</i> , <b>2019</b> , 132, e771-e777	2.4	9
65	Pathogenesis of osteoporotic hip fractures. <i>Clinical Cornerstone</i> , <b>2003</b> , Suppl 2, S22-9		9
64	Parathyroid hormone for the treatment of osteoporosis. <i>Obstetrical and Gynecological Survey</i> , <b>2004</b> , 59, 826-32	2.4	9
63	Review of risedronate in the treatment of osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2001</b> , 2, 2011-25	4	9
62	Osteoporosis update from the 2010 santa fe bone symposium. <i>Journal of Clinical Densitometry</i> , <b>2011</b> , 14, 1-21	3.5	8
61	New management options for osteoporosis with emphasis on SERMs. <i>Climacteric</i> , <b>2015</b> , 18 Suppl 2, 56-61	3.1	7
60	Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide. <i>Calcified Tissue International</i> , <b>2018</b> , 102, 627-633	3.9	7
59	Lebanese guidelines for osteoporosis assessment and treatment: who to test? What measures to use? When to treat?. <i>Journal of Clinical Densitometry</i> , <b>2005</b> , 8, 148-63	3.5	7
58	Pharmacologic intervention for prevention of fractures in osteopenic and osteoporotic postmenopausal women: Systemic review and meta-analysis. <i>Bone Reports</i> , <b>2020</b> , 13, 100729	2.6	7
57	Skeletal responses to romosozumab after 12 months of denosumab. <i>JBMR Plus</i> , <b>2021</b> , 5, e10512	3.9	7
56	Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. <i>Osteoporosis International</i> , <b>2015</b> , 26, 327-37	5.3	6
55	A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data. <i>Calcified Tissue International</i> , <b>2013</b> , 92, 59-67	3.9	6
54	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. <i>Obstetrical and Gynecological Survey</i> , <b>2009</b> , 64, 805-807	2.4	6
53	Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14 Suppl 2, 74-8	6.3	6
52	Treatment of hyperthyroidism. <i>Annual Review of Medicine</i> , <b>1980</b> , 31, 385-404	17.4	6
51	Use of bone densitometry results for decisions about therapy for osteoporosis. <i>Annals of Internal Medicine</i> , <b>1996</b> , 125, 623	8	6
50	Overdiagnosis and Overtreatment of Osteoporosis: A Wolf in Sheep's Clothing. <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 1754-7	6.3	5

49	Use of highly potent bisphosphonates in the treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , <b>2003</b> , 1, 116-22	5.4	5
48	Relation between body composition and biochemical markers of bone turnover among early postmenopausal women. <i>Journal of Clinical Densitometry</i> , <b>2000</b> , 3, 365-71	3.5	5
47	Bisphosphonates and osteonecrosis of the jaw. <i>Annals of Internal Medicine</i> , <b>2006</b> , 145, 791-2; author reply 792	8	4
46	Bone age as a correction factor for the analysis of trabecular bone score (TBS) in children. <i>Archives of Osteoporosis</i> , <b>2019</b> , 14, 26	2.9	4
45	Role of bone-forming agents in the management of osteoporosis. <i>Aging Clinical and Experimental Research</i> , <b>2021</b> , 33, 775-791	4.8	4
44	History of risedronate. <i>Bone</i> , <b>2020</b> , 137, 115407	4.7	3
43	Osteoporosis update from the 2012 Santa Fe Bone Symposium. <i>Journal of Clinical Densitometry</i> , <b>2013</b> , 16, 584-600	3.5	3
42	Response to: Comment on: "Denosumab Rapidly Increases Cortical Bone in Key Locations of the Femur: A 3D Bone Mapping Study in Women With Osteoporosis". <i>Journal of Bone and Mineral Research</i> , <b>2015</b> , 30, 1939-40	6.3	3
41	Bisphosphonate therapy: To stop or not to stop?. <i>BoneKEy Osteovision</i> , <b>2007</b> , 4, 78-82		3
40	The clinical and epidemiologic consequences of redefining treatment criteria: who should be treated?. <i>Salud Publica De Mexico</i> , <b>2009</b> , 51 Suppl 1, S46-51	1.7	3
39	Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVEExtend. <i>Menopause</i> , <b>2020</b> , 27, 1137-1142	2.5	3
38	Treating Paget's Disease of Bone <b>1992</b> , 2, 22-28		2
37	Mid-molecule parathyroid hormone assay comparison. <i>Clinical Biochemistry</i> , <b>1986</b> , 19, 41-5	3.5	2
36	Efficacy and Safety of Osteoporosis Treatment <b>2019</b> , 43-57		2
35	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , <b>2021</b> , 36, 1225-1234	6.3	2
34	Use of highly potent bisphosphonates in the treatment of osteoporosis. <i>Current Osteoporosis Reports</i> , <b>2003</b> , 1, 116-122	5.4	1
33	How does raloxifene reduce fracture risk?. <i>Menopause</i> , <b>2002</b> , 9, 306-8	2.5	1
32	Bone Health and Hormonal Contraception <b>2014</b> , 287-306		1

31	Bisphosphonates for Postmenopausal Osteoporosis <b>2018</b> , 545-552		1
30	Drug holidays in women treated for postmenopausal osteoporosis. <i>Menopause</i> , <b>2018</b> , 25, 1152-1154	2.5	1
29	Interactions Between Muscle and Bone <b>2018</b> , 1055-1062		1
28	Advanced Techniques of Bone Mass Measurements and Strength in Adults <b>2018</b> , 260-271		1
27	Transplantation Osteoporosis <b>2018</b> , 424-435		1
26	Prevention of Falls <b>2018</b> , 526-533		1
25	Management of Osteoporosis in Patients with Chronic Kidney Disease <b>2018</b> , 505-509		1
24	The role of osteoanabolic agents in the management of patients with osteoporosis. <i>Postgraduate Medicine</i> , 1-11	3.7	1
23	How to Interpret Surrogate Markers of Efficacy in Osteoporosis. <i>Journal of Bone and Mineral Research</i> , <b>2005</b> , 20, 1263-1264	6.3	0
22	Denosumab for the treatment of osteoporosis <b>2021</b> , 1737-1755		0
21	Biochemical Markers of Bone Turnover in Osteoporosis <b>2018</b> , 293-301		0
20	Osteoanabolic therapy for osteoporosis in women. <i>Climacteric</i> , <b>2021</b> , 1-7	3.1	0
19	Other Safety Concerns <b>2016</b> , 279-293		
18	Denosumab for the Treatment of Osteoporosis <b>2013</b> , 1923-1934		
17	Preventing postmenopausal osteoporosis <b>2013</b> , 70-83		
16	Who Should Be Screened: Who Should Be Treated? <b>2008</b> , 1449-1460		
15	Risedronate Once A Week. <i>Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders</i> , <b>2003</b> , 2, 421		
14	Osteology: further debate. <i>Journal of Bone and Mineral Research</i> , <b>1999</b> , 14, 1017	6.3	

- 13 Osteoporosis from the Perspective of an Endocrinologist. *Baylor University Medical Center Proceedings*, **1996**, 9, 47-52 0.6
- 12 ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIIEY. *Osteoporosis and Bone Diseases*, **2011**, 14, 37-39<sup>0.8</sup>
- 11 Emerging Therapies 211-226
- 10 RE-INVIGORATING THE OSTEOPOROSIS MESSAGE. *Endocrine Practice*, **2016**, 22, 1130-1 3.2
- 9 Inflammation-Induced Bone Loss in the Rheumatic Diseases **2018**, 459-466
- 8 Sarcopenia and Osteoporosis **2018**, 498-504
- 7 Cellular Bioenergetics of Bone **2018**, 1004-1011
- 6 Gonadal Steroids **2018**, 194-204
- 5 Osteoporosis in Men **2018**, 443-449
- 4 Effects on the Skeleton from Medications Used to Treat Nonskeletal Disorders **2018**, 482-486
- 3 Obesity and Skeletal Health **2018**, 492-497
- 2 Parathyroid Hormone and Abaloparatide Treatment for Osteoporosis **2018**, 559-566
- 1 Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.. *Menopause*, **2022**, 29, 304-308 2.5